Stay updated on BA058 Clinical Trial for Postmenopausal Fracture Prevention

Sign up to get notified when there's something new on the BA058 Clinical Trial for Postmenopausal Fracture Prevention page.
Latest website image capture
Clouds background image

Latest updates to the BA058 Clinical Trial for Postmenopausal Fracture Prevention page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the context of a study related to evaluating the safety and efficacy of BA058 (Abaloparatide) for fracture prevention in postmenopausal women with severe osteoporosis.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:38.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that healthy ambulatory postmenopausal women aged 50 to 85 with a diagnosis of osteoporosis are eligible. The criteria now also include specific bone mineral density requirements and fracture history considerations.
    Difference
    27%
    Check dated 2024-05-22T21:37:23.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:31:20.000Z thumbnail image

Stay in the know with updates to BA058 Clinical Trial for Postmenopausal Fracture Prevention

Enter your email address, and we'll notify you when there's something new on the BA058 Clinical Trial for Postmenopausal Fracture Prevention page.